Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in Advanced HER2-Altered NSCLC
NCT04818333Phase 2Active, not recruiting
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Apr 2021; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04818333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818333.